Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Canadian (TSX) Pharma Industry Analysis

UpdatedJan 10, 2026
DataAggregated Company Financials
Companies59
  • 7D0.6%
  • 3M-4.1%
  • 1Y17.8%
  • YTD0.6%

Over the last 7 days, the Pharma industry has remained flat. As for the the longer term, the industry is up 18% over the past 12 months. Earnings are forecast to grow by 67% annually.

Industry Valuation and Performance

Has the Canadian Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 10 Jan 2026CA$16.6bCA$11.3b-CA$1,960,493,268.1216.8x-8.5x1.5x
Mon, 08 Dec 2025CA$14.3bCA$11.3b-CA$1,917,133,404.8614.4x-7.5x1.3x
Wed, 05 Nov 2025CA$15.8bCA$11.3b-CA$2,048,944,554.2631.3x-7.7x1.4x
Fri, 03 Oct 2025CA$17.4bCA$11.2b-CA$2,035,948,891.5840.1x-8.5x1.5x
Sun, 31 Aug 2025CA$18.1bCA$11.8b-CA$2,512,553,770.6739.9x-7.2x1.5x
Tue, 29 Jul 2025CA$11.8bCA$11.8b-CA$2,539,661,561.5517.1x-4.6x1x
Thu, 26 Jun 2025CA$9.5bCA$11.7b-CA$2,523,241,308.8216.8x-3.8x0.8x
Sat, 24 May 2025CA$23.8bCA$11.8b-CA$2,386,824,912.0317.8x-10x2x
Mon, 21 Apr 2025CA$9.7bCA$12.0b-CA$2,565,498,718.6519.1x-3.8x0.8x
Wed, 19 Mar 2025CA$10.7bCA$12.3b-CA$2,640,199,995.4019.1x-4.1x0.9x
Fri, 14 Feb 2025CA$12.4bCA$12.1b-CA$2,212,969,547.0023.8x-5.6x1x
Sun, 12 Jan 2025CA$12.4bCA$12.2b-CA$2,417,209,526.7728.7x-5.1x1x
Tue, 10 Dec 2024CA$13.6bCA$12.0b-CA$2,581,746,931.1223x-5.3x1.1x
Thu, 07 Nov 2024CA$19.1bCA$11.9b-CA$2,771,044,784.6618x-6.9x1.6x
Sat, 05 Oct 2024CA$18.6bCA$11.6b-CA$2,680,134,100.3027.4x-6.9x1.6x
Mon, 02 Sep 2024CA$17.1bCA$11.6b-CA$2,690,218,404.9420.2x-6.4x1.5x
Wed, 31 Jul 2024CA$20.1bCA$11.8b-CA$3,212,184,320.3420x-6.2x1.7x
Fri, 28 Jun 2024CA$20.4bCA$11.8b-CA$3,239,151,617.4318.8x-6.3x1.7x
Sun, 26 May 2024CA$21.8bCA$11.9b-CA$3,490,501,699.0812.8x-6.2x1.8x
Tue, 23 Apr 2024CA$23.2bCA$12.0b-CA$3,476,028,729.958.2x-6.7x1.9x
Thu, 21 Mar 2024CA$22.6bCA$11.8b-CA$3,477,097,457.189.5x-6.5x1.9x
Sat, 17 Feb 2024CA$22.3bCA$12.0b-CA$4,643,332,391.6110.4x-4.8x1.9x
Mon, 15 Jan 2024CA$20.3bCA$12.3b-CA$6,744,251,485.009.3x-3x1.7x
Wed, 13 Dec 2023CA$17.3bCA$12.4b-CA$6,782,848,879.008.2x-2.6x1.4x
Fri, 10 Nov 2023CA$16.9bCA$12.5b-CA$7,314,992,422.0010.3x-2.3x1.4x
Sun, 08 Oct 2023CA$18.6bCA$12.4b-CA$7,334,632,248.0015x-2.5x1.5x
Tue, 05 Sep 2023CA$18.0bCA$13.0b-CA$7,911,625,052.0013.3x-2.3x1.4x
Thu, 03 Aug 2023CA$15.2bCA$13.3b-CA$9,743,091,053.0012.1x-1.6x1.1x
Sat, 01 Jul 2023CA$14.8bCA$13.2b-CA$9,514,993,365.0011.4x-1.6x1.1x
Mon, 29 May 2023CA$14.9bCA$13.4b-CA$10,471,665,836.0010.2x-1.4x1.1x
Wed, 26 Apr 2023CA$14.9bCA$13.5b-CA$9,997,376,351.0010.8x-1.5x1.1x
Fri, 24 Mar 2023CA$17.2bCA$13.8b-CA$10,095,082,425.009.1x-1.7x1.2x
Sun, 19 Feb 2023CA$20.4bCA$13.6b-CA$10,307,884,782.0010.5x-2x1.5x
Tue, 17 Jan 2023CA$20.9bCA$13.5b-CA$10,099,014,878.0013.4x-2.1x1.5x
Price to Earnings Ratio

-2.1x


Total Market Cap: CA$20.9bTotal Earnings: -CA$10,099,014,878.00Total Revenue: CA$13.5bTotal Market Cap vs Earnings and Revenue0%0%0%
Canadian Pharma Industry Price to Earnings3Y Average -4.7x202420252026
Current Industry PE
  • Investors are relatively neutral on the Canadian Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 1.4x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have improved over the last three years.
  • Meanwhile revenues for these companies have declined 5.7% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Trends

Which industries have driven the changes within the Canadian Healthcare industry?

CA Market1.91%
Healthcare1.48%
Pharma0.57%
Pharma0.57%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
GTII Green Thumb IndustriesCA$11.261.4%
+CA$37.1m		6.3%PE43x
VREO Vireo GrowthCA$0.853.7%
+CA$32.0m		6.3%PS3.4x
WEED Canopy GrowthCA$1.735.5%
+CA$30.8m		-50.9%PS2.1x
TRUL Trulieve CannabisCA$12.091.5%
+CA$30.5m		70.5%PS1.2x
TSND TerrAscendCA$1.126.7%
+CA$21.3m		41.8%PS0.8x

Latest News

HITI
CA$3.71
High Tide
7D
-3.4%
1Y
-16.1%
ALGO
CA$0.095
Light AI
7D
-26.9%
1Y
-87.3%
CWEB
CA$0.51
Charlotte's Web Holdings
7D
-8.9%
1Y
200.0%
VRNO
CA$1.77
Verano Holdings
7D
-2.2%
1Y
3.5%

VRNO: New State Licenses And Dispensary Expansion Will Support Future Upside

Analysts have trimmed their fair value estimate for Verano Holdings from about US$5.03 to roughly US$4.96 per share, citing updated views on revenue growth, profit margins, and a lower future P/E assumption. What's in the News Opened Zen Leaf Charleston, the sixth dispensary in West Virginia and the 159th location across the U.S., adding to an existing footprint that includes a 40,000 square foot cultivation and processing facility in the state (Key Developments).
CURA
CA$3.50
Curaleaf Holdings
7D
-2.2%
1Y
69.9%

CURA: Regulatory Shifts Will Widen Moat And Support Destination Brand Position

Analysts have lifted their price target on Curaleaf Holdings to C$5.00 from C$4.81, pointing to regulatory momentum and what they see as a stronger product offering that could help the company reinforce its position with consumers. Analyst Commentary Recent commentary has focused on how regulatory shifts and Curaleaf's product positioning could influence the company’s valuation and execution over time.
TSND
CA$1.12
TerrAscend
7D
6.7%
1Y
41.8%

TSND: Expanded Mid Atlantic Footprint And Licensing Will Support Higher Profitability

Analysts have nudged their price target on TerrAscend toward about $2.00, reflecting updated views that incorporate higher projected profit margins, a lower assumed future P/E multiple near 43, and adjusted revenue expectations. What's in the News Closed the previously announced transaction with Union Chill Cannabis Company LLC, adding a high performing dispensary in Hunterdon County and bringing TerrAscend's New Jersey retail footprint to four dispensaries (Key Developments).
GTII
CA$11.26
Green Thumb Industries
7D
1.4%
1Y
6.3%

Here's Why Green Thumb Industries (CSE:GTII) Can Manage Its Debt Responsibly

Jan 06
Here's Why Green Thumb Industries (CSE:GTII) Can Manage Its Debt Responsibly
MDP
CA$2.88
Medexus Pharmaceuticals
7D
-6.8%
1Y
-28.7%

Does Medexus Pharmaceuticals (TSE:MDP) Have A Healthy Balance Sheet?

Jan 03
Does Medexus Pharmaceuticals (TSE:MDP) Have A Healthy Balance Sheet?
VREO
CA$0.85
Vireo Growth
7D
3.7%
1Y
6.3%
TRUL
CA$12.09
Trulieve Cannabis
7D
1.5%
1Y
70.5%
CPH
CA$15.46
Cipher Pharmaceuticals
7D
3.8%
1Y
8.3%

CPH: Share Repurchases And Rising Margins Will Support Stronger Future Earnings

Cipher Pharmaceuticals' analyst price target has been raised from 14.50 dollars to 18.60 dollars, as analysts cite slightly stronger expected revenue growth, modestly higher profit margins, and a richer future earnings multiple as justification for the upward revision. What's in the News Cipher Pharmaceuticals completed the latest tranche of its share repurchase program between July 1, 2025 and September 30, 2025, buying back 141,700 shares, or 0.56 percent of its float, for CAD 2.18 million (Key Developments) Under the buyback announced on May 1, 2025, the company has now repurchased a total of 371,978 shares, representing 1.46 percent of shares outstanding, for aggregate consideration of CAD 5.12 million (Key Developments) Valuation Changes The consensus analyst price target has risen significantly from 14.50 dollars to 18.60 dollars, reflecting a materially higher fair value assessment.
GRIN
CA$0.60
Grown Rogue International
7D
-14.3%
1Y
-33.3%

Is Grown Rogue International (CSE:GRIN) Using Debt Sensibly?

Dec 25
Is Grown Rogue International (CSE:GRIN) Using Debt Sensibly?
WEED
CA$1.73
Canopy Growth
7D
5.5%
1Y
-50.9%

WEED: Medical Expansion Will Drive Future Upside For Shares

Analysts have nudged their price target on Canopy Growth higher to reflect an improved fair value estimate, rising from approximately $3.30 to $3.76. This revision is supported by slightly stronger projected revenue growth, a notable uplift in expected profit margins, and a lower anticipated future price to earnings multiple.
CRON
CA$3.73
Cronos Group
7D
1.1%
1Y
31.8%
SKNY
CA$2.27
LIR Life Sciences
7D
16.4%
1Y
n/a
BNXT
CA$0.59
BioNxt Solutions
7D
-9.2%
1Y
43.9%